Your browser doesn't support javascript.
loading
A phase I study of anti-BCMA CAR T cell therapy in relapsed/refractory multiple myeloma and plasma cell leukemia.
Li, Chunrui; Cao, Wenyue; Que, Yimei; Wang, Qiuxiang; Xiao, Yi; Gu, Chaojiang; Wang, Di; Wang, Jue; Jiang, Lijun; Xu, Hao; Xu, Jinhuan; Zhou, Xiaoxi; Hong, Zhenya; Wang, Na; Huang, Liang; Zhang, Shangkun; Chen, Liting; Mao, Xia; Xiao, Min; Zhang, Wei; Meng, Li; Cao, Yang; Zhang, Tongcun; Li, Jian; Zhou, Jianfeng.
Afiliación
  • Li C; Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
  • Cao W; Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, Hubei, China.
  • Que Y; Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
  • Wang Q; Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, Hubei, China.
  • Xiao Y; Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
  • Gu C; Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, Hubei, China.
  • Wang D; Wuhan No.1 Hospital, Wuhan, Hubei, China.
  • Wang J; Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
  • Jiang L; Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, Hubei, China.
  • Xu H; College of Life Science and Health, Wuhan University of Science and Technology, Wuhan, Hubei, China.
  • Xu J; Wuhan Bio-Raid Biotechnology Co., Ltd., Wuhan, Hubei, China.
  • Zhou X; Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
  • Hong Z; Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, Hubei, China.
  • Wang N; Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
  • Huang L; Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, Hubei, China.
  • Zhang S; Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
  • Chen L; Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, Hubei, China.
  • Mao X; Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
  • Xiao M; Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, Hubei, China.
  • Zhang W; Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
  • Meng L; Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, Hubei, China.
  • Cao Y; Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
  • Zhang T; Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, Hubei, China.
  • Li J; Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
  • Zhou J; Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, Hubei, China.
Clin Transl Med ; 11(3): e346, 2021 03.
Article en En | MEDLINE | ID: mdl-33784005
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Linfocitos T / Leucemia de Células Plasmáticas / Inmunoterapia Adoptiva / Antígeno de Maduración de Linfocitos B / Receptores Quiméricos de Antígenos / Mieloma Múltiple Tipo de estudio: Prognostic_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Transl Med Año: 2021 Tipo del documento: Article País de afiliación: China Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Linfocitos T / Leucemia de Células Plasmáticas / Inmunoterapia Adoptiva / Antígeno de Maduración de Linfocitos B / Receptores Quiméricos de Antígenos / Mieloma Múltiple Tipo de estudio: Prognostic_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Transl Med Año: 2021 Tipo del documento: Article País de afiliación: China Pais de publicación: Estados Unidos